BML-210

• Description :

  BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].

• CAS Number :

  [537034-17-6]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H361, H372, H410

• Target :

  Apoptosis; HDAC

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BML-210.html

• Concentration :

  10mM

• Purity :

  98.04

• Solubility :

  DMSO : ≥ 30 mg/mL

• Smiles :

  O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O

• Molecular Formula :

  C20H25N3O2

• Molecular Weight :

  339.43

• Precautions :

  H302, H361, H372, H410

• References & Citations :

  [1]Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40 (12) : 5378–5388.|[2]Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16 (8) : 18252–18269.|[3]Zhuolong Zhou, et al. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5 (11) :1320-1335.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC4